Studying polyglutamine diseases in Drosophila

Experimental Neurology

Volumn 274, Issue , 2015, Pages 25-41

  Xu, Zhen ^a,e   Joel Tito, Antonio ^a,c,d,e   Rui, Yan Ning ^a,e   Zhang, Sheng ^a,b,c,d,e  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b Department of Neurobiology and Anatomy ^*  (United States)

^c UT Health   (United States)

^d UNIVERSITY OF TEXAS   (United States)

^e UNIVERSITY OF TEXAS   (United States)

Author keywords

Atrophin 1; Dentatorubral pallidoluysian atrophy; Drosophila model; DRPLA; HD; HTT; Huntingtin; Huntington's disease; Machado Joseph disease; Polyglutamine diseases; PolyQ diseases; SBMA; SCA1; Spinobulbar muscular atrophy; Spinocerebellar ataxia

Indexed keywords

ATAXIN 1; ATROPHIN 1; HUNTINGTIN; REPRESSOR PROTEIN; UNCLASSIFIED DRUG; DROSOPHILA PROTEIN; NERVE PROTEIN; PEPTIDE; POLYGLUTAMINE;

ATXN1 GENE; AXONAL TRAFFICKING; CALCIUM HOMEOSTASIS; CELL MIGRATION; DEGENERATIVE DISEASE; DROSOPHILA; DROSOPHILA MELANOGASTER; DRUG DEVELOPMENT; EXPERIMENTAL DESIGN; EYE; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC MODEL; HTT GENE; HUMAN; HUNTINGTON CHOREA; MACROAUTOPHAGY; MOLECULAR DYNAMICS; NERVE CELL DEGENERATION; NERVE CELL DIFFERENTIATION; NEUROMODULATION; NEUROPATHOLOGY; NEUROTOXICITY; NEUROTRANSMISSION; NONHUMAN; POLYGLUTAMINE DISEASE; POLYGLUTAMINE TRACT; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; SEQUENCE HOMOLOGY; SURVIVAL RATE; TRANSCRIPTION REGULATION; TRINUCLEOTIDE REPEAT; ANIMAL; GENETICS; PATHOLOGY;

ANIMALS; DROSOPHILA; DROSOPHILA PROTEINS; HUMANS; NERVE TISSUE PROTEINS; NEURODEGENERATIVE DISEASES; PEPTIDES; TRINUCLEOTIDE REPEATS;

EID: 84946558464     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2015.08.002     Document Type: Review

References (287)

1. Agrawal N., et al. Identification of combinatorial drug regimens for treatment of Huntington's disease using Drosophila. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:3777-3781.
2. Andrade M.A., Bork P. HEAT repeats in the Huntington's disease protein. Nat. Genet. 1995, 11:115-116.
3. Andrade M.A., Petosa C., O'Donoghue S.I., Muller C.W., Bork P. Comparison of ARM and HEAT protein repeats. J. Mol. Biol. 2001, 309:1-18.
4. Andrew S.E., et al. The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease. Nat. Genet. 1993, 4:398-403.
5. Apostol B.L., et al. A cell-based assay for aggregation inhibitors as therapeutics of polyglutamine-repeat disease and validation in Drosophila. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:5950-5955.
6. Arias A.M. Drosophila melanogaster and the development of biology in the 20th century. Methods Mol. Biol. 2008, 420:1-25.
7. Arrasate M., Mitra S., Schweitzer E.S., Segal M.R., Finkbeiner S. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 2004, 431:805-810.
8. Arribat Y., et al. A huntingtin peptide inhibits polyQ-huntingtin associated defects. PLoS One 2013, 8:e68775.
9. Bailey C.K., Andriola I.F., Kampinga H.H., Merry D.E. Molecular chaperones enhance the degradation of expanded polyglutamine repeat androgen receptor in a cellular model of spinal and bulbar muscular atrophy. Hum. Mol. Genet. 2002, 11:515-523.
10. Barbaro B.A., et al. Comparative study of naturally occurring huntingtin fragments in Drosophila points to exon 1 as the most pathogenic species in Huntington's disease. Hum. Mol. Genet. 2015, 24:913-925.
11. Basler K., Hafen E. Dynamics of Drosophila eye development and temporal requirements of sevenless expression. Development 1989, 107:723-731.
12. Bates G.P., Harper P., Jones L. Huntington's Disease 2002, Oxford Medical Publications. 3rd edition.
13. Bauer P.O., Nukina N. The pathogenic mechanisms of polyglutamine diseases and current therapeutic strategies. J. Neurochem. 2009, 110:1737-1765.
14. Bellen H.J., Tong C., Tsuda H. 100years of Drosophila research and its impact on vertebrate neuroscience: a history lesson for the future. Nat. Rev. Neurosci. 2010, 11:514-522.
15. Benzer S. From the gene to behavior. JAMA 1971, 218:1015-1022.
16. Bier E. Drosophila, the golden bug, emerges as a tool for human genetics. Nat. Rev. Genet. 2005, 6:9-23.
17. Bier E., Ackerman L., Barbel S., Jan L., Jan Y.N. Identification and characterization of a neuron-specific nuclear antigen in Drosophila. Science 1988, 240:913-916.
18. Bilen J., Bonini N.M. Drosophila as a model for human neurodegenerative disease. Annu. Rev. Genet. 2005, 39:153-171.
19. Bilen J., Bonini N.M. Genome-wide screen for modifiers of ataxin-3 neurodegeneration in Drosophila. PLoS Genet. 2007, 3:1950-1964.
20. Bilen J., Liu N., Burnett B.G., Pittman R.N., Bonini N.M. MicroRNA pathways modulate polyglutamine-induced neurodegeneration. Mol. Cell 2006, 24:157-163.
21. Blackman R.K., Sanicola M., Raftery L.A., Gillevet T., Gelbart W.M. An extensive 3' cis-regulatory region directs the imaginal disk expression of decapentaplegic, a member of the TGF-beta family in Drosophila. Development 1991, 111:657-666.
22. Bonini N.M. Drosophila as a genetic approach to human neurodegenerative disease. Parkinsonism Relat. Disord. 2001, 7:171-175.
23. Bonini N.M., Fortini M.E. Human neurodegenerative disease modeling using Drosophila. Annu. Rev. Neurosci. 2003, 26:627-656.
24. Borrell-Pages M., Zala D., Humbert S., Saudou F. Huntington's disease: from huntingtin function and dysfunction to therapeutic strategies. Cell. Mol. Life Sci. 2006, 63:2642-2660.
25. Bortvedt S.F., McLear J.A., Messer A., Ahern-Rindell A.J., Wolfgang W.J. Cystamine and intrabody co-treatment confers additional benefits in a fly model of Huntington's disease. Neurobiol. Dis. 2010, 40:130-134.
26. Bowtell D.D., Lila T., Michael W.M., Hackett D., Rubin G.M. Analysis of the enhancer element that controls expression of sevenless in the developing Drosophila eye. Proc. Natl. Acad. Sci. U. S. A. 1991, 88:6853-6857.
27. Branco J., et al. Comparative analysis of genetic modifiers in Drosophila points to common and distinct mechanisms of pathogenesis among polyglutamine diseases. Hum. Mol. Genet. 2008, 17:376-390.
28. Brand A.H., Perrimon N. Targeted gene expression as a means of altering cell fates and generating dominant phenotypes. Development 1993, 118:401-415.
29. Brown T.R., et al. Deletion of the steroid-binding domain of the human androgen receptor gene in one family with complete androgen insensitivity syndrome: evidence for further genetic heterogeneity in this syndrome. Proc. Natl. Acad. Sci. U. S. A. 1988, 85:8151-8155.
30. Bukau B., Weissman J., Horwich A. Molecular chaperones and protein quality control. Cell 2006, 125:443-451.
31. Cagan R.L., Ready D.F. The emergence of order in the Drosophila pupal retina. Dev. Biol. 1989, 136:346-362.
32. Cattaneo E., et al. Loss of normal huntingtin function: new developments in Huntington's disease research. Trends Neurosci. 2001, 24:182-188.
33. Cattaneo E., Zuccato C., Tartari M. Normal huntingtin function: an alternative approach to Huntington's disease. Nat. Rev. Neurosci. 2005, 6:919-930.
34. Caughey B., Lansbury P.T. Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu. Rev. Neurosci. 2003, 26:267-298.
35. Caviston J.P., Holzbaur E.L. Huntingtin as an essential integrator of intracellular vesicular trafficking. Trends Cell Biol. 2009, 19:147-155.
36. Chan H.Y., Bonini N.M. Drosophila models of polyglutamine diseases. Methods Mol. Biol. 2003, 217:241-251.
37. Chan H.Y., Warrick J.M., Gray-Board G.L., Paulson H.L., Bonini N.M. Mechanisms of chaperone suppression of polyglutamine disease: selectivity, synergy and modulation of protein solubility in Drosophila. Hum. Mol. Genet. 2000, 9:2811-2820.
38. Chan H.Y., Warrick J.M., Andriola I., Merry D., Bonini N.M. Genetic modulation of polyglutamine toxicity by protein conjugation pathways in Drosophila. Hum. Mol. Genet. 2002, 11:2895-2904.
39. Chen H.K., et al. Interaction of Akt-phosphorylated ataxin-1 with 14-3-3 mediates neurodegeneration in spinocerebellar ataxia type 1. Cell 2003, 113:457-468.
40. Chen-Plotkin A.S., et al. Decreased association of the transcription factor Sp1 with genes downregulated in Huntington's disease. Neurobiol. Dis. 2006, 22:233-241.
41. Clark I.E., et al. Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature 2006, 441:1162-1166.
42. Cortes C.J., Qin K., Cook J., Solanki A., Mastrianni J.A. Rapamycin delays disease onset and prevents PrP plaque deposition in a mouse model of Gerstmann-Straussler-Scheinker disease. J. Neurosci. 2012, 32:12396-12405.
43. Craig E.A., Weissman J.S., Horwich A.L. Heat shock proteins and molecular chaperones: mediators of protein conformation and turnover in the cell. Cell 1994, 78:365-372.
44. Cummings C.J., Zoghbi H.Y. Fourteen and counting: unraveling trinucleotide repeat diseases. Hum. Mol. Genet. 2000, 9:909-916.
45. Cummings C.J., Zoghbi H.Y. Trinucleotide repeats: mechanisms and pathophysiology. Annu. Rev. Genomics Hum. Genet. 2000, 1:281-328.
46. Cummings C.J., et al. Chaperone suppression of aggregation and altered subcellular proteasome localization imply protein misfolding in SCA1. Nat. Genet. 1998, 19:148-154.
47. David G., et al. Cloning of the SCA7 gene reveals a highly unstable CAG repeat expansion. Nat. Genet. 1997, 17:65-70.
48. Davies S.W., et al. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 1997, 90:537-548.
49. Davies J.E., Sarkar S., Rubinsztein D.C. The ubiquitin proteasome system in Huntington's disease and the spinocerebellar ataxias. BMC Biochem. 2007, 8(Suppl. 1):S2.
50. Deka R., et al. Normal CAG repeat variation at the DRPLA locus in world populations. Am. J. Hum. Genet. 1995, 57:508-511.
51. Dietz K.N., et al. The Drosophila Huntington's disease gene ortholog dhtt influences chromatin regulation during development. Hum. Mol. Genet. 2015, 24:330-345.
52. DiFiglia M., et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 1997, 277:1990-1993.
53. Dragatsis I., Efstratiadis A., Zeitlin S. Mouse mutant embryos lacking huntingtin are rescued from lethality by wild-type extraembryonic tissues. Development 1998, 125:1529-1539.
54. Dragatsis I., Levine M.S., Zeitlin S. Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice. Nat. Genet. 2000, 26:300-306.
55. Dragovic Z., Broadley S.A., Shomura Y., Bracher A., Hartl F.U. Molecular chaperones of the Hsp110 family act as nucleotide exchange factors of Hsp70s. EMBO J. 2006, 25:2519-2528.
56. Driscoll M., Gerstbrein B. Dying for a cause: invertebrate genetics takes on human neurodegeneration. Nat. Rev. Genet. 2003, 4:181-194.
57. Dunah A.W., et al. Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. Science 2002, 296:2238-2243.
58. Duvick L., et al. SCA1-like disease in mice expressing wild-type ataxin-1 with a serine to aspartic acid replacement at residue 776. Neuron 2010, 67:929-935.
59. Duyao M.P., et al. Inactivation of the mouse Huntington's disease gene homolog Hdh. Science 1995, 269:407-410.
60. Ellis M.C., O'Neill E.M., Rubin G.M. Expression of Drosophila glass protein and evidence for negative regulation of its activity in non-neuronal cells by another DNA-binding protein. Development 1993, 119:855-865.
61. Emamian E.S., et al. Serine 776 of ataxin-1 is critical for polyglutamine-induced disease in SCA1 transgenic mice. Neuron 2003, 38:375-387.
62. Erkner A., et al. Grunge, related to human Atrophin-like proteins, has multiple functions in Drosophila development. Development 2002, 129:1119-1129.
63. Fanto M., et al. The tumor-suppressor and cell adhesion molecule Fat controls planar polarity via physical interactions with Atrophin, a transcriptional co-repressor. Development 2003, 130:763-774.
64. Farrar A.M., et al. Cognitive deficits in transgenic and knock-in HTT mice parallel those in Huntington's disease. J. Huntingt. Dis. 2014, 3:145-158.
65. Feany M.B. Studying human neurodegenerative diseases in flies and worms. J. Neuropathol. Exp. Neurol. 2000, 59:847-856.
66. Feany M.B., La Spada A.R. Polyglutamines stop traffic: axonal transport as a common target in neurodegenerative diseases. Neuron 2003, 40:1-2.
67. Fernandez-Funez P., et al. Identification of genes that modify ataxin-1-induced neurodegeneration. Nature 2000, 408:101-106.
68. Fortini M.E., Skupski M.P., Boguski M.S., Hariharan I.K. A survey of human disease gene counterparts in the Drosophila genome. J. Cell Biol. 2000, 150:F23-F30.
69. Franceschini N. Information Processing in the Visual Sysytem of Arthropods 1972, 75-82. Springer, Berlin. R. Wehner (Ed.).
70. Frederick C., et al. Rapamycin ester analog CCI-779/Temsirolimus alleviates tau pathology and improves motor deficit in mutant tau transgenic mice. J. Alzheimers Dis. 2015, 44:1145-1156.
71. Friedman M.J., et al. Polyglutamine domain modulates the TBP-TFIIB interaction: implications for its normal function and neurodegeneration. Nat. Neurosci. 2007, 10:1519-1528.
72. Gafni J., et al. Inhibition of calpain cleavage of huntingtin reduces toxicity: accumulation of calpain/caspase fragments in the nucleus. J. Biol. Chem. 2004, 279:20211-20220.
73. Gil J.M., Rego A.C. Mechanisms of neurodegeneration in Huntington's disease. Eur. J. Neurosci. 2008, 27:2803-2820.
74. Godin J.D., et al. Huntingtin is required for mitotic spindle orientation and mammalian neurogenesis. Neuron 2010, 67:392-406.
75. Goehler H., et al. A protein interaction network links GIT1, an enhancer of huntingtin aggregation, to Huntington's disease. Mol. Cell 2004, 15:853-865.
76. Goffredo D., et al. Calcium-dependent cleavage of endogenous wild-type huntingtin in primary cortical neurons. J. Biol. Chem. 2002, 277:39594-39598.
77. Gohil V.M., et al. Meclizine is neuroprotective in models of Huntington's disease. Hum. Mol. Genet. 2011, 20:294-300.
78. Goldberg Y.P., et al. Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract. Nat. Genet. 1996, 13:442-449.
79. Graham R.K., et al. Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin. Cell 2006, 125:1179-1191.
80. Gray M., et al. Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J. Neurosci. 2008, 28:6182-6195.
81. Greene J.C., et al. Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:4078-4083.
82. Gunawardena S., et al. Disruption of axonal transport by loss of huntingtin or expression of pathogenic polyQ proteins in Drosophila. Neuron 2003, 40:25-40.
83. Gusella J.F., MacDonald M.E. Molecular genetics: unmasking polyglutamine triggers in neurodegenerative disease. Nat. Rev. Neurosci. 2000, 1:109-115.
84. Gusella J., MacDonald M. No post-genetics era in human disease research. Nat. Rev. Genet. 2002, 3:72-79.
85. Gutekunst C.A., et al. Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology. J. Neurosci. 1999, 19:2522-2534.
86. Hackam A.S., et al. The influence of huntingtin protein size on nuclear localization and cellular toxicity. J. Cell Biol. 1998, 141:1097-1105.
87. Harjes P., Wanker E.E. The hunt for huntingtin function: interaction partners tell many different stories. Trends Biochem. Sci. 2003, 28:425-433.
88. Hay B.A., Wolff T., Rubin G.M. Expression of baculovirus P35 prevents cell death in Drosophila. Development 1994, 120:2121-2129.
89. He C., Klionsky D.J. Regulation mechanisms and signaling pathways of autophagy. Annu. Rev. Genet. 2009, 43:67-93.
90. Heikkinen T., et al. Characterization of neurophysiological and behavioral changes, MRI brain volumetry and 1H MRS in zQ175 knock-in mouse model of Huntington's disease. PLoS One 2012, 7:e50717.
91. Helmlinger D., et al. Ataxin-7 is a subunit of GCN5 histone acetyltransferase-containing complexes. Hum. Mol. Genet. 2004, 13:1257-1265.
92. Helmlinger D., Hardy S., Eberlin A., Devys D., Tora L. Both normal and polyglutamine-expanded ataxin-7 are components of TFTC-type GCN5 histone acetyltransferase-containing complexes. Biochem. Soc. Symp. 2006, 155-163.
93. Helmlinger D., et al. Glutamine-expanded ataxin-7 alters TFTC/STAGA recruitment and chromatin structure leading to photoreceptor dysfunction. PLoS Biol. 2006, 4:e67.
94. Hodgson J.G., et al. A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron 1999, 23:181-192.
95. Holmberg M., et al. Spinocerebellar ataxia type 7 (SCA7): a neurodegenerative disorder with neuronal intranuclear inclusions. Hum. Mol. Genet. 1998, 7:913-918.
96. Huang K., Fingar D.C. Growing knowledge of the mTOR signaling network. Semin. Cell Dev. Biol. 2014, 36:79-90.
97. Huynh D.P., Del Bigio M.R., Ho D.H., Pulst S.M. Expression of ataxin-2 in brains from normal individuals and patients with Alzheimer's disease and spinocerebellar ataxia 2. Ann. Neurol. 1999, 45:232-241.
98. Ikeuchi T., et al. Dentatorubral-pallidoluysian atrophy: clinical features are closely related to unstable expansions of trinucleotide (CAG) repeat. Ann. Neurol. 1995, 37:769-775.
99. Ikeuchi T., et al. Dentatorubral-pallidoluysian atrophy (DRPLA): close correlation of CAG repeat expansions with the wide spectrum of clinical presentations and prominent anticipation. Semin. Cell Biol. 1995, 6:37-44.
100. Imarisio S., et al. Huntington's disease: from pathology and genetics to potential therapies. Biochem. J. 2008, 412:191-209.
101. Imbert G., et al. Cloning of the gene for spinocerebellar ataxia 2 reveals a locus with high sensitivity to expanded CAG/glutamine repeats. Nat. Genet. 1996, 14:285-291.
102. Jackson G.R., et al. Polyglutamine-expanded human huntingtin transgenes induce degeneration of Drosophila photoreceptor neurons. Neuron 1998, 21:633-642.
103. Jia D.D., et al. Lithium chloride alleviates neurodegeneration partly by inhibiting activity of GSK3beta in a SCA3 Drosophila model. Cerebellum 2013, 12:892-901.
104. Jiang T., et al. Temsirolimus promotes autophagic clearance of amyloid-beta and provides protective effects in cellular and animal models of Alzheimer's disease. Pharmacol. Res. 2014, 81:54-63.
105. Jiang T., et al. Temsirolimus attenuates tauopathy in vitro and in vivo by targeting tau hyperphosphorylation and autophagic clearance. Neuropharmacology 2014, 85:121-130.
106. Johansen T., Lamark T. Selective autophagy mediated by autophagic adapter proteins. Autophagy 2011, 7:279-296.
107. Jung J., Bonini N. CREB-binding protein modulates repeat instability in a Drosophila model for polyQ disease. Science 2007, 315:1857-1859.
108. Kaltenbach L.S., et al. Huntingtin interacting proteins are genetic modifiers of neurodegeneration. PLoS Genet. 2007, 3:e82.
109. Kanuka H., et al. Cytosol-endoplasmic reticulum interplay by Sec61alpha translocon in polyglutamine-mediated neurotoxicity in Drosophila. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:11723-11728.
110. Karim F.D., Rubin G.M. Ectopic expression of activated Ras1 induces hyperplastic growth and increased cell death in Drosophila imaginal tissues. Development 1998, 125:1-9.
111. Kawaguchi Y., et al. CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1. Nat. Genet. 1994, 8:221-228.
112. Kazantsev A., et al. A bivalent Huntingtin binding peptide suppresses polyglutamine aggregation and pathogenesis in Drosophila. Nat. Genet. 2002, 30:367-376.
113. Kazemi-Esfarjani P., Benzer S. Genetic suppression of polyglutamine toxicity in Drosophila. Science 2000, 287:1837-1840.
114. Kazemi-Esfarjani P., Benzer S. Suppression of polyglutamine toxicity by a Drosophila homolog of myeloid leukemia factor 1. Hum. Mol. Genet. 2002, 11:2657-2672.
115. Kegel K.B., et al. Huntingtin is present in the nucleus, interacts with the transcriptional corepressor C-terminal binding protein, and represses transcription. J. Biol. Chem. 2002, 277:7466-7476.
116. Kim Y.J., et al. Caspase 3-cleaved N-terminal fragments of wild-type and mutant huntingtin are present in normal and Huntington's disease brains, associate with membranes, and undergo calpain-dependent proteolysis. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:12784-12789.
117. King-Jones K., Thummel C.S. Nuclear receptors-a perspective from Drosophila. Nat. Rev. Genet. 2005, 6:311-323.
118. Kirkin V., McEwan D.G., Novak I., Dikic I. A role for ubiquitin in selective autophagy. Mol. Cell 2009, 34:259-269.
119. Klement I.A., et al. Ataxin-1 nuclear localization and aggregation: role in polyglutamine-induced disease in SCA1 transgenic mice [see comments]. Cell 1998, 95:41-53.
120. Kobayashi Y., et al. Chaperones Hsp70 and Hsp40 suppress aggregate formation and apoptosis in cultured neuronal cells expressing truncated androgen receptor protein with expanded polyglutamine tract. J. Biol. Chem. 2000, 275:8772-8778.
121. Koide R., et al. Unstable expansion of CAG repeat in hereditary dentatorubral-pallidoluysian atrophy (DRPLA). Nat. Genet. 1994, 6:9-13.
122. Komure O., et al. DNA analysis in hereditary dentatorubral-pallidoluysian atrophy: correlation between CAG repeat length and phenotypic variation and the molecular basis of anticipation. Neurology 1995, 45:143-149.
123. Koob M.D., et al. Rapid cloning of expanded trinucleotide repeat sequences from genomic DNA. Nat. Genet. 1998, 18:72-75.
124. Koyano S., et al. Neuronal intranuclear inclusions in spinocerebellar ataxia type 2: triple-labeling immunofluorescent study. Neurosci. Lett. 1999, 273:117-120.
125. Kraft C., Peter M., Hofmann K. Selective autophagy: ubiquitin-mediated recognition and beyond. Nat. Cell Biol. 2010, 12:836-841.
126. Krench M., Littleton J.T. Modeling Huntington disease in Drosophila: insights into axonal transport defects and modifiers of toxicity. Fly 2013, 7:229-236.
127. Kretzschmar D., Hasan G., Sharma S., Heisenberg M., Benzer S. The swiss cheese mutant causes glial hyperwrapping and brain degeneration in Drosophila. J. Neurosci. 1997, 17:7425-7432.
128. Kuemmerle S., et al. Huntington aggregates may not predict neuronal death in Huntington's disease. Ann. Neurol. 1999, 46:842-849.
129. Kuo Y., Ren S., Lao U., Edgar B.A., Wang T. Suppression of polyglutamine protein toxicity by co-expression of a heat-shock protein 40 and a heat-shock protein 110. Cell Death Dis. 2013, 4:e833.
130. La Spada A.R., Wilson E.M., Lubahn D.B., Harding A.E., Fischbeck K.H. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 1991, 352:77-79.
131. La Spada A.R., Paulson H.L., Fischbeck K.H. Trinucleotide repeat expansion in neurological disease. Ann. Neurol. 1994, 36:814-822.
132. Lam Y.C., et al. ATAXIN-1 interacts with the repressor Capicua in its native complex to cause SCA1 neuropathology. Cell 2006, 127:1335-1347.
133. Lamark T., Johansen T. Aggrephagy: selective disposal of protein aggregates by macroautophagy. Int. J. Cell Biol. 2012, 2012:736905.
134. Laplante M., Sabatini D.M. mTOR signaling at a glance. J. Cell Sci. 2009, 122:3589-3594.
135. Laplante M., Sabatini D.M. mTOR signaling in growth control and disease. Cell 2012, 149:274-293.
136. Latouche M., et al. A conditional pan-neuronal Drosophila model of spinocerebellar ataxia 7 with a reversible adult phenotype suitable for identifying modifier genes. J. Neurosci. 2007, 27:2483-2492.
137. Lee W.C., Yoshihara M., Littleton J.T. Cytoplasmic aggregates trap polyglutamine-containing proteins and block axonal transport in a Drosophila model of Huntington's disease. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:3224-3229.
138. Li S.H., Li X.J. Huntingtin-protein interactions and the pathogenesis of Huntington's disease. Trends Genet. 2004, 20:146-154.
139. Li M., et al. Nuclear inclusions of the androgen receptor protein in spinal and bulbar muscular atrophy. Ann. Neurol. 1998, 44:249-254.
140. Li M., et al. Nonneural nuclear inclusions of androgen receptor protein in spinal and bulbar muscular atrophy. Am. J. Pathol. 1998, 153:695-701.
141. Li Z., Karlovich C.A., Fish M.P., Scott M.P., Myers R.M. A putative Drosophila homolog of the Huntington's disease gene. Hum. Mol. Genet. 1999, 8:1807-1815.
142. Li S.H., et al. Interaction of Huntington disease protein with transcriptional activator Sp1. Mol. Cell. Biol. 2002, 22:1277-1287.
143. Lim J., et al. Opposing effects of polyglutamine expansion on native protein complexes contribute to SCA1. Nature 2008, 452:713-718.
144. Lin X., Cummings C.J., Zoghbi H.Y. Expanding our understanding of polyglutamine diseases through mouse models. Neuron 1999, 24:499-502.
145. Lu B. Recent advances in using Drosophila to model neurodegenerative diseases. Apoptosis 2009, 14(8):1008-1020.
146. Lu B., Vogel H. Drosophila models of neurodegenerative diseases. Annu. Rev. Pathol. 2009, 4:315-342.
147. Lu B., et al. Identification of NUB1 as a suppressor of mutant Huntington toxicity via enhanced protein clearance. Nat. Neurosci. 2013, 16:562-570.
148. Lunkes A., et al. Proteases acting on mutant huntingtin generate cleaved products that differentially build up cytoplasmic and nuclear inclusions. Mol. Cell 2002, 10:259-269.
149. Luo L., Tully T., White K. Human amyloid precursor protein ameliorates behavioral deficit of flies deleted for Appl gene. Neuron 1992, 9:595-605.
150. MacDonald M.E. Huntingtin: alive and well and working in middle management. Sci. STKE 2003, 2003:pe48.
151. Majumder S., Richardson A., Strong R., Oddo S. Inducing autophagy by rapamycin before, but not after, the formation of plaques and tangles ameliorates cognitive deficits. PLoS One 2011, 6:e25416.
152. Mangiarini L., et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996, 87:493-506.
153. Marsh J.L., Thompson L.M. Drosophila in the study of neurodegenerative disease. Neuron 2006, 52:169-178.
154. Marsh J.L., et al. Expanded polyglutamine peptides alone are intrinsically cytotoxic and cause neurodegeneration in Drosophila. Hum. Mol. Genet. 2000, 9:13-25.
155. Martin D.D., Ladha S., Ehrnhoefer D.E., Hayden M.R. Autophagy in Huntington disease and huntingtin in autophagy. Trends Neurosci. 2014, 38(1):26-35.
156. Martinez-Vicente M., et al. Cargo recognition failure is responsible for inefficient autophagy in Huntington's disease. Nat. Neurosci. 2010, 13:567-576.
157. Matsumoto T., et al. The androgen receptor in health and disease. Annu. Rev. Physiol. 2013, 75:201-224.
158. McMahon S.J., Pray-Grant M.G., Schieltz D., Yates J.R., Grant P.A. Polyglutamine-expanded spinocerebellar ataxia-7 protein disrupts normal SAGA and SLIK histone acetyltransferase activity. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:8478-8482.
159. Menalled L.B. Knock-in mouse models of Huntington's disease. NeuroRx 2005, 2:465-470.
160. Menalled L.B., et al. Comprehensive behavioral and molecular characterization of a new knock-in mouse model of Huntington's disease: zQ175. PLoS One 2012, 7:e49838.
161. Menzies F.M., et al. Autophagy induction reduces mutant ataxin-3 levels and toxicity in a mouse model of spinocerebellar ataxia type 3. Brain 2010, 133:93-104.
162. Min K.T., Benzer S. Spongecake and eggroll: two hereditary diseases in Drosophila resemble patterns of human brain degeneration. Curr. Biol. 1997, 7:885-888.
163. Min K.T., Benzer S. Preventing neurodegeneration in the Drosophila mutant bubblegum. Science 1999, 284:1985-1988.
164. Mlodzik M., Hiromi Y., Weber U., Goodman C.S., Rubin G.M. The Drosophila seven-up gene, a member of the steroid receptor gene superfamily, controls photoreceptor cell fates. Cell 1990, 60:211-224.
165. Monks D.A., et al. Overexpression of wild-type androgen receptor in muscle recapitulates polyglutamine disease. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:18259-18264.
166. Moses K., Rubin G.M. Glass encodes a site-specific DNA-binding protein that is regulated in response to positional signals in the developing Drosophila eye. Genes Dev. 1991, 5:583-593.
167. Nagai Y., et al. Prevention of polyglutamine oligomerization and neurodegeneration by the peptide inhibitor QBP1 in Drosophila. Hum. Mol. Genet. 2003, 12:1253-1259.
168. Nakamura K., et al. SCA17, a novel autosomal dominant cerebellar ataxia caused by an expanded polyglutamine in TATA-binding protein. Hum. Mol. Genet. 2001, 10:1441-1448.
169. Napoletano F., et al. Polyglutamine Atrophin provokes neurodegeneration in Drosophila by repressing fat. EMBO J. 2011, 30:945-958.
170. Nasir J., et al. Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell 1995, 81:811-823.
171. Nedelsky N.B., et al. Native functions of the androgen receptor are essential to pathogenesis in a Drosophila model of spinobulbar muscular atrophy. Neuron 2010, 67:936-952.
172. Nisoli I., et al. Neurodegeneration by polyglutamine Atrophin is not rescued by induction of autophagy. Cell Death Differ. 2010, 17:1577-1587.
173. Ochaba J., et al. Potential function for the Huntingtin protein as a scaffold for selective autophagy. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:16889-16894.
174. Orr H.T., et al. Expansion of an unstable trinucleotide CAG repeat in spinocerebellar ataxia type 1. Nat. Genet. 1993, 4:221-226.
175. Palhan V.B., et al. Polyglutamine-expanded ataxin-7 inhibits STAGA histone acetyltransferase activity to produce retinal degeneration. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:8472-8477.
176. Pandey U.B., et al. HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS. Nature 2007, 447:859-863.
177. Panov A.V., et al. Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat. Neurosci. 2002, 5:731-736.
178. Park J., et al. Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature 2006, 441:1157-1161.
179. Paulson H.L. Protein fate in neurodegenerative proteinopathies: polyglutamine diseases join the (mis)fold. Am. J. Hum. Genet. 1999, 64:339-345.
180. Paulson H.L., et al. Intranuclear inclusions of expanded polyglutamine protein in spinocerebellar ataxia type 3. Neuron 1997, 19:333-344.
181. Perutz M.F., Johnson T., Suzuki M., Finch J.T. Glutamine repeats as polar zippers: their possible role in inherited neurodegenerative diseases. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:5355-5358.
182. Pulst S.M., et al. Moderate expansion of a normally biallelic trinucleotide repeat in spinocerebellar ataxia type 2. Nat. Genet. 1996, 14:269-276.
183. Quigley C.A., et al. Complete deletion of the androgen receptor gene: definition of the null phenotype of the androgen insensitivity syndrome and determination of carrier status. J. Clin. Endocrinol. Metab. 1992, 74:927-933.
184. Quiring R., Walldorf U., Kloter U., Gehring W.J. Homology of the eyeless gene of Drosophila to the Small eye gene in mice and Aniridia in humans. Science 1994, 265:785-789.
185. Raftery L.A., Sanicola M., Blackman R.K., Gelbart W.M. The relationship of decapentaplegic and engrailed expression in Drosophila imaginal disks: do these genes mark the anterior-posterior compartment boundary?. Development 1991, 113:27-33.
186. Rajakulendran S., Kaski D., Hanna M.G. Neuronal P/Q-type calcium channel dysfunction in inherited disorders of the CNS. Nat. Rev. Neurol. 2012, 8:86-96.
187. Rampelt H., et al. Metazoan Hsp70 machines use Hsp110 to power protein disaggregation. EMBO J. 2012, 31:4221-4235.
188. Ratovitski T., et al. N-terminal proteolysis of full-length mutant huntingtin in an inducible PC12 cell model of Huntington's disease. Cell Cycle 2007, 6:2970-2981.
189. Ravikumar B., et al. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat. Genet. 2004, 36:585-595.
190. Raviol H., Sadlish H., Rodriguez F., Mayer M.P., Bukau B. Chaperone network in the yeast cytosol: Hsp110 is revealed as an Hsp70 nucleotide exchange factor. EMBO J. 2006, 25:2510-2518.
191. Reddy P.H., et al. Behavioural abnormalities and selective neuronal loss in HD transgenic mice expressing mutated full-length HD cDNA. Nat. Genet. 1998, 20:198-202.
192. Robinow S., White K. The locus elav of Drosophila melanogaster is expressed in neurons at all developmental stages. Dev. Biol. 1988, 126:294-303.
193. Robinow S., Campos A.R., Yao K.M., White K. The elav gene product of Drosophila, required in neurons, has three RNP consensus motifs. Science 1988, 242:1570-1572.
194. Romero E., et al. Suppression of neurodegeneration and increased neurotransmission caused by expanded full-length huntingtin accumulating in the cytoplasm. Neuron 2008, 57:27-40.
195. Ross C.A. When more is less: pathogenesis of glutamine repeat neurodegenerative diseases. Neuron 1995, 15:493-496.
196. Ross C.A. Intranuclear neuronal inclusions: a common pathogenic mechanism for glutamine-repeat neurodegenerative diseases?. Neuron 1997, 19:1147-1150.
197. Ross C.A., Poirier M.A. Opinion: what is the role of protein aggregation in neurodegeneration?. Nat. Rev. Mol. Cell Biol. 2005, 6:891-898.
198. Ross C.A., et al. Huntington's disease and dentatorubral-pallidoluysian atrophy: proteins, pathogenesis and pathology. Brain Pathol. 1997, 7:1003-1016.
199. Ross C.A., et al. Huntington disease and the related disorder, dentatorubral-pallidoluysian atrophy (DRPLA). Medicine (Baltimore) 1997, 76:305-338.
200. Ross C.A., et al. Polyglutamine pathogenesis. Philos. Trans. R. Soc. Lond. B Biol. Sci. 1999, 354:1005-1011.
201. Rubin G.M., Lewis E.B. A brief history of Drosophila's contributions to genome research. Science 2000, 287:2216-2218.
202. Rubin G.M., Spradling A.C. Genetic transformation of Drosophila with transposable element vectors. Science 1982, 218:348-353.
203. Rubin G.M., et al. Comparative genomics of the eukaryotes. Science 2000, 287:2204-2215.
204. Rubinsztein D.C. How does the Huntington's disease mutation damage cells?. Sci. Aging Knowledge Environ. 2003, 2003:PE26.
205. Rubinsztein D.C., Carmichael J. Huntington's disease: molecular basis of neurodegeneration. Expert Rev. Mol. Med. 2003, 5:1-21.
206. Rui Y.N., et al. Huntingtin functions as a scaffold for selective macroautophagy. Nat. Cell Biol. 2015, 17:262-275.
207. Sanpei K., et al. Identification of the spinocerebellar ataxia type 2 gene using a direct identification of repeat expansion and cloning technique, DIRECT. Nat. Genet. 1996, 14:277-284.
208. Sathasivam K., et al. Formation of polyglutamine inclusions in non-CNS tissue. Hum. Mol. Genet. 1999, 8:813-822.
209. Sathasivam K., et al. Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:2366-2370.
210. Schilling G., et al. Nuclear accumulation of truncated atrophin-1 fragments in a transgenic mouse model of DRPLA. Neuron 1999, 24:275-286.
211. Schulte J., Sepp K.J., Wu C., Hong P., Littleton J.T. High-content chemical and RNAi screens for suppressors of neurotoxicity in a Huntington's disease model. PLoS One 2011, 6:e23841.
212. Seong I.S., et al. Huntingtin facilitates polycomb repressive complex 2. Hum. Mol. Genet. 2010, 19:573-583.
213. Seto E.S., Bellen H.J. The ins and outs of Wingless signaling. Trends Cell Biol. 2004, 14:45-53.
214. Shaid S., Brandts C.H., Serve H., Dikic I. Ubiquitination and selective autophagy. Cell Death Differ. 2013, 20:21-30.
215. Shaner L., Sousa R., Morano K.A. Characterization of Hsp70 binding and nucleotide exchange by the yeast Hsp110 chaperone Sse1. Biochemistry 2006, 45:15075-15084.
216. Shirasaki D.I., et al. Network organization of the huntingtin proteomic interactome in mammalian brain. Neuron 2012, 75:41-57.
217. Shorter J. The mammalian disaggregase machinery: Hsp110 synergizes with Hsp70 and Hsp40 to catalyze protein disaggregation and reactivation in a cell-free system. PLoS One 2011, 6:e26319.
218. Siegfried E., Perrimon N. Drosophila wingless: a paradigm for the function and mechanism of Wnt signaling. Bioessays 1994, 16:395-404.
219. Siegfried E., Wilder E.L., Perrimon N. Components of wingless signalling in Drosophila. Nature 1994, 367:76-80.
220. Sipione S., Cattaneo E. Modeling huntington's disease in cells, flies, and mice. Mol. Neurobiol. 2001, 23:21-51.
221. Sisodia S.S. Nuclear inclusions in glutamine repeat disorders: are they pernicious, coincidental, or beneficial?. Cell 1998, 95:1-4.
222. Skinner P.J., et al. Ataxin-1 with an expanded glutamine tract alters nuclear matrix-associated structures. Nature 1997, 389:971-974.
223. Snell R.G., et al. Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington's disease. Nat. Genet. 1993, 4:393-397.
224. Song W., et al. Proteolytic release and nuclear translocation of Notch-1 are induced by presenilin-1 and impaired by pathogenic presenilin-1 mutations. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:6959-6963.
225. Sontag E.M., et al. Methylene blue modulates huntingtin aggregation intermediates and is protective in Huntington's disease models. J. Neurosci. 2012, 32:11109-11119.
226. Spradling A., et al. New roles for model genetic organisms in understanding and treating human disease: report from the 2006 Genetics Society of America meeting. Genetics 2006, 172:2025-2032.
227. Steffan J.S., et al. The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:6763-6768.
228. Steffan J.S., et al. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 2001, 413:739-743.
229. Steffan J.S., et al. SUMO modification of Huntingtin and Huntington's disease pathology. Science 2004, 304:100-104.
230. Steller H., Grether M.E. Programmed cell death in Drosophila. Neuron 1994, 13:1269-1274.
231. Struhl G., Greenwald I. Presenilin is required for activity and nuclear access of Notch in Drosophila [see comments]. Nature 1999, 398:522-525.
232. Takeyama K., et al. Androgen-dependent neurodegeneration by polyglutamine-expanded human androgen receptor in Drosophila. Neuron 2002, 35:855-864.
233. Tang T.S., et al. Huntingtin and huntingtin-associated protein 1 influence neuronal calcium signaling mediated by inositol-(1,4,5) triphosphate receptor type 1. Neuron 2003, 39:227-239.
234. The Huntington's Disease Collaborative Research Group A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993, 72:971-983.
235. Thompson L.M., et al. IKK phosphorylates Huntingtin and targets it for degradation by the proteasome and lysosome. J. Cell Biol. 2009, 187:1083-1099.
236. Tomlinson A., Ready D.F. Neuronal differentiation in Drosophila ommatidium. Dev. Biol. 1987, 120:366-376.
237. Tomlinson A., Ready D.F. Cell fate in the Drosophila ommatidium. Dev. Biol. 1987, 123:264-275.
238. Toneff T., et al. Comparison of huntingtin proteolytic fragments in human lymphoblast cell lines and human brain. J. Neurochem. 2002, 82:84-92.
239. Treisman J.E., Heberlein U. Eye development in Drosophila: formation of the eye field and control of differentiation. Curr. Top. Dev. Biol. 1998, 39:119-158.
240. Tsuda H., et al. The AXH domain of Ataxin-1 mediates neurodegeneration through its interaction with Gfi-1/Senseless proteins. Cell 2005, 122:633-644.
241. Van Raamsdonk J.M., Murphy Z., Slow E.J., Leavitt B.R., Hayden M.R. Selective degeneration and nuclear localization of mutant huntingtin in the YAC128 mouse model of Huntington disease. Hum. Mol. Genet. 2005, 14:3823-3835.
242. Van Raamsdonk J.M., et al. Loss of wild-type huntingtin influences motor dysfunction and survival in the YAC128 mouse model of Huntington disease. Hum. Mol. Genet. 2005, 14:1379-1392.
243. van Roon-Mom W.M., Reid S.J., Faull R.L., Snell R.G. TATA-binding protein in neurodegenerative disease. Neuroscience 2005, 133:863-872.
244. Venken K.J., He Y., Hoskins R.A., Bellen H.J. P[acman]: a BAC transgenic platform for targeted insertion of large DNA fragments in D. melanogaster. Science 2006, 314:1747-1751.
245. Venken K.J., et al. Versatile P[acman] BAC libraries for transgenesis studies in Drosophila melanogaster. Nat. Methods 2009, 6:431-434.
246. Venken K.J., et al. MiMIC: a highly versatile transposon insertion resource for engineering Drosophila melanogaster genes. Nat. Methods 2011, 8:737-743.
247. Vonsattel J.P., DiFiglia M. Huntington disease. J. Neuropathol. Exp. Neurol. 1998, 57:369-384.
248. Vonsattel J.P., et al. Neuropathological classification of Huntington's disease. J. Neuropathol. Exp. Neurol. 1985, 44:559-577.
249. Wang L., Tsai C.C. Atrophin proteins: an overview of a new class of nuclear receptor corepressors. Nucl. Recept. Signal. 2008, 6:e009.
250. Wang L., Rajan H., Pitman J.L., McKeown M., Tsai C.C. Histone deacetylase-associating Atrophin proteins are nuclear receptor corepressors. Genes Dev. 2006, 20:525-530.
251. Wang L., Charroux B., Kerridge S., Tsai C.C. Atrophin recruits HDAC1/2 and G9a to modify histone H3K9 and to determine cell fates. EMBO Rep. 2008, 9:555-562.
252. Wang A.M., et al. Activation of Hsp70 reduces neurotoxicity by promoting polyglutamine protein degradation. Nat. Chem. Biol. 2013, 9:112-118.
253. Wangler M.F., Yamamoto S., Bellen H.J. Fruit flies in biomedical research. Genetics 2015, 99(3):639-653.
254. Warner C.L., et al. X-linked spinomuscular atrophy: a kindred with associated abnormal androgen receptor binding. Neurology 1992, 42:2181-2184.
255. Warrick J.M., et al. Expanded polyglutamine protein forms nuclear inclusions and causes neural degeneration in Drosophila. Cell 1998, 93:939-949.
256. Warrick J.M., et al. Suppression of polyglutamine-mediated neurodegeneration in Drosophila by the molecular chaperone HSP70. Nat. Genet. 1999, 23:425-428.
257. Warrick J.M., et al. Ataxin-3 suppresses polyglutamine neurodegeneration in Drosophila by a ubiquitin-associated mechanism. Mol. Cell 2005, 18:37-48.
258. Weiss K.R., Kimura Y., Lee W.C., Littleton J.T. Huntingtin aggregation kinetics and their pathological role in a Drosophila Huntington's disease model. Genetics 2012, 190:581-600.
259. Wellington C.L., Hayden M.R. Caspases and neurodegeneration: on the cutting edge of new therapeutic approaches. Clin. Genet. 2000, 57:1-10.
260. Wellington C.L., et al. Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and nonneuronal cells. J. Biol. Chem. 2000, 275:19831-19838.
261. Wellington C.L., et al. Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease. J. Neurosci. 2002, 22:7862-7872.
262. White J.K., et al. Huntingtin is required for neurogenesis and is not impaired by the Huntington's disease CAG expansion. Nat. Genet. 1997, 17:404-410.
263. Wolff T., Ready D.F. The beginning of pattern formation in the Drosophila compound eye: the morphogenetic furrow and the second mitotic wave. Development 1991, 113:841-850.
264. Wolff T., Ready D.F. Pattern formation in the Drosophila retina. The development of Drosophila melanogaster 1993, 1277-1326. Cold Spring Harbor Press, Cold Spring Harbor. M.B.A. Martinez-Arias (Ed.).
265. Yang Y., et al. Mitochondrial pathology and muscle and dopaminergic neuron degeneration caused by inactivation of Drosophila Pink1 is rescued by Parkin. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:10793-10798.
266. Ye Y., Fortini M.E. Characterization of Drosophila Presenilin and its colocalization with Notch during development. Mech. Dev. 1998, 79:199-211.
267. Yi J., et al. Sodium valproate alleviates neurodegeneration in SCA3/MJD via suppressing apoptosis and rescuing the hypoacetylation levels of histone H3 and H4. PLoS One 2013, 8:e54792.
268. Zeitlin S., Liu J.P., Chapman D.L., Papaioannou V.E., Efstratiadis A. Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue. Nat. Genet. 1995, 11:155-163.
269. Zeron M.M., et al. Increased sensitivity to N-methyl-d-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease. Neuron 2002, 33:849-860.
270. Zhai W., Jeong H., Cui L., Krainc D., Tjian R. In vitro analysis of huntingtin-mediated transcriptional repression reveals multiple transcription factor targets. Cell 2005, 123:1241-1253.
271. Zhai R.G., et al. Drosophila NMNAT maintains neural integrity independent of its NAD synthesis activity. PLoS Biol. 2006, 4:e416.
272. Zhang S., Xu L., Lee J., Xu T. Drosophila atrophin homolog functions as a transcriptional corepressor in multiple developmental processes. Cell 2002, 108:45-56.
273. Zhang S., Feany M.B., Saraswati S., Littleton J.T., Perrimon N. Inactivation of Drosophila Huntingtin affects long-term adult functioning and the pathogenesis of a Huntington's disease model. Dis. Model. Mech. 2009, 2:247-266.
274. Zhang S., Binari R., Zhou R., Perrimon N. A genomewide RNA interference screen for modifiers of aggregates formation by mutant Huntingtin in Drosophila. Genetics 2010, 184:1165-1179.
275. Zheng S., et al. Deletion of the huntingtin polyglutamine stretch enhances neuronal autophagy and longevity in mice. PLoS Genet. 2010, 6:e1000838.
276. Zheng S., Ghitani N., Blackburn J.S., Liu J.P., Zeitlin S.O. A series of N-terminal epitope tagged Hdh knock-in alleles expressing normal and mutant huntingtin: their application to understanding the effect of increasing the length of normal Huntingtin's polyglutamine stretch on CAG140 mouse model pathogenesis. Mol. Brain 2012, 5:28.
277. Zhuchenko O., et al. Autosomal dominant cerebellar ataxia (SCA6) associated with small polyglutamine expansions in the alpha 1A-voltage-dependent calcium channel. Nat. Genet. 1997, 15:62-69.
278. Zoghbi H.Y. Spinocerebellar ataxia type 1. Clin. Neurosci. 1995, 3:5-11.
279. Zoghbi H.Y., Orr H.T. Polyglutamine diseases: protein cleavage and aggregation. Curr. Opin. Neurobiol. 1999, 9:566-570.
280. Zoghbi H.Y., Orr H.T. Glutamine repeats and neurodegeneration. Annu. Rev. Neurosci. 2000, 23:217-247.
281. Zoghbi H.Y., Orr H.T. Pathogenic mechanisms of a polyglutamine-mediated neurodegenerative disease, spinocerebellar ataxia type 1. J. Biol. Chem. 2009, 284:7425-7429.
282. Zoncu R., Efeyan A., Sabatini D.M. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat. Rev. Mol. Cell Biol. 2011, 12:21-35.
283. Zuccato C., Cattaneo E. Role of brain-derived neurotrophic factor in Huntington's disease. Prog. Neurobiol. 2007, 81:294-330.
284. Zuccato C., et al. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 2001, 293:493-498.
285. Zuccato C., et al. Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nat. Genet. 2003, 35:76-83.
286. Zuccato C., et al. Progressive loss of BDNF in a mouse model of Huntington's disease and rescue by BDNF delivery. Pharmacol. Res. 2005, 52:133-139.
287. Zuccato C., et al. Widespread disruption of repressor element-1 silencing transcription factor/neuron-restrictive silencer factor occupancy at its target genes in Huntington's disease. J. Neurosci. 2007, 27:6972-6983.